NDASUBCUTANEOUSPOWDERPriority Review
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
YUVIWEL (navepegritide) by Ascendis Pharma is cnp. Approved for achondroplasia. First approved in 2026.
Drug data last refreshed 20h ago
Mechanism of Action
CNP. CNP binds to natriuretic peptide receptor-B (NPR-B), which inhibits the mitogen activated protein kinase signaling (MAPK) pathway. Achondroplasia is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3) leading to overactive downstream signaling. The overly…
Indications (1)
Clinical Trials (3)
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
Started Dec 2024
24 enrolled
Achondroplasia
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
Started Jul 2024
22 enrolled
Achondroplasia
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Started Jan 2024
72 enrolled
Achondroplasia
Worked on YUVIWEL at Ascendis Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.